Wegovy is the first semaglutide injection specifically approved for weight management — not diabetes. It uses a higher dose than Ozempic and has produced some of the most impressive weight-loss results in clinical history. Here is everything South Africans need to know about getting Wegovy, what it costs, how it compares to Ozempic, and whether it is right for you.
Medical disclaimer: Wegovy is a prescription medication that should only be used under medical supervision. This article is for informational purposes only. Never start, stop, or change medication without consulting your doctor. If you experience serious side effects, contact your healthcare provider immediately.
Wegovy (semaglutide 2.4mg) is a once-weekly injectable medication manufactured by Novo Nordisk, the same company behind Ozempic. While Ozempic was developed for type 2 diabetes, Wegovy was designed from the ground up as a weight management drug.
The active ingredient in both is identical — semaglutide, a GLP-1 receptor agonist. The difference is the dose: Wegovy goes up to 2.4mg per week, while Ozempic maxes out at 2mg. That extra dose translates to meaningfully more weight loss in clinical trials.
Wegovy was approved by the US FDA in June 2021, the European Medicines Agency in January 2022, and has been registered by SAHPRA (South African Health Products Regulatory Authority) for use in South Africa.
Semaglutide mimics a naturally occurring hormone called GLP-1 (glucagon-like peptide-1), which plays multiple roles in metabolism:
This is the question most South Africans ask first. Both contain semaglutide. Both are weekly injections from Novo Nordisk. But there are important differences.
| Feature | Wegovy | Ozempic |
|---|---|---|
| Approved for | Chronic weight management | Type 2 diabetes |
| Active ingredient | Semaglutide | Semaglutide |
| Maximum dose | 2.4mg weekly | 2mg weekly |
| Dose escalation | 5 steps over 16 weeks | 3 steps over 8+ weeks |
| SA cost (monthly) | R4,500 – R6,500 | R3,500 – R5,500 |
| Average weight loss | ~15% body weight | ~10-12% body weight |
| Medical aid cover | Rarely covered for weight loss | Sometimes covered for diabetes |
| SA availability | Intermittent stock shortages | More widely available |
| Pen type | Pre-filled, single-dose FlexTouch | Multi-dose FlexTouch pen |
For a detailed head-to-head comparison including clinical trial data, read our full guide: Wegovy vs Ozempic in South Africa.
The off-label reality: Because Wegovy stock has been unreliable in South Africa, many doctors prescribe Ozempic off-label for weight management at higher doses (1mg or 2mg). This is legal and common practice, but it means the dosing schedule differs from Wegovy's formal protocol. Discuss this with your prescribing doctor.
Wegovy uses a gradual 5-step dose escalation to minimise gastrointestinal side effects. Rushing the escalation increases nausea, vomiting, and the likelihood of discontinuation. Your doctor will typically follow this schedule:
| Month | Dose | What to expect |
|---|---|---|
| Month 1 (Weeks 1-4) | 0.25mg | Introductory dose. Minimal appetite change. Some mild nausea possible. Your body is adjusting to semaglutide |
| Month 2 (Weeks 5-8) | 0.5mg | Appetite reduction begins. Portion sizes naturally decrease. Nausea may increase briefly |
| Month 3 (Weeks 9-12) | 1mg | Noticeable appetite suppression. Most patients report 3-5% weight loss by this point |
| Month 4 (Weeks 13-16) | 1.7mg | Strong appetite control. Cravings significantly reduced. Weight loss accelerating |
| Month 5+ (Week 17 onward) | 2.4mg (maintenance) | Full therapeutic dose. Maximum appetite suppression. Ongoing steady weight loss |
Tip: If side effects are severe at any dose level, your doctor may extend that dose for an additional 4 weeks before escalating. There is no rush. Slower escalation = better tolerance = longer adherence = more total weight lost.
Wegovy is not available over the counter. You need a prescription from a registered South African doctor. The standard prescribing criteria are:
Cost is the biggest barrier for most South Africans. Wegovy is not cheap, and medical aid coverage remains limited.
| Dose tier | Approximate monthly cost | Notes |
|---|---|---|
| 0.25mg (Month 1) | R4,500 – R5,000 | Starting dose — lower end of range |
| 0.5mg (Month 2) | R4,500 – R5,000 | Same pen type, same price band |
| 1mg (Month 3) | R5,000 – R5,500 | Mid-range pricing |
| 1.7mg (Month 4) | R5,500 – R6,000 | Higher dose, higher cost |
| 2.4mg (Maintenance) | R5,800 – R6,500 | Full maintenance dose — ongoing monthly |
First-year total: Expect to spend approximately R60,000 – R75,000 on Wegovy in the first year, including the escalation phase. This works out to roughly R5,000 – R6,250 per month on average.
The situation with medical aid coverage for Wegovy in South Africa is evolving but still restrictive:
Save on costs: Ask your pharmacist about loyalty programmes. Dis-Chem and Clicks both have rewards programmes that accumulate points on prescription purchases. Some compounding pharmacies in Johannesburg, Cape Town, and Durban offer compounded semaglutide at lower prices, though quality and regulation vary.
Wegovy shares the same side-effect profile as Ozempic because the active ingredient is identical. However, the higher dose means side effects can be more pronounced, particularly during escalation.
For a comprehensive breakdown including long-term data, see our semaglutide side effects guide.
Availability has been the biggest frustration for South African patients. Global demand for semaglutide has outstripped Novo Nordisk's manufacturing capacity, and South Africa — as a smaller market — has experienced periodic shortages.
Counterfeit warning: The global semaglutide shortage has created a black market. Counterfeit Wegovy and Ozempic pens have been seized in South Africa containing unknown substances, incorrect doses, or no active ingredient at all. NEVER purchase from social media sellers, informal traders, or unregistered online stores. Only obtain semaglutide from a licensed pharmacy with a valid prescription.
Wegovy is not a magic injection. Without dietary changes and exercise, results will be modest and weight regain after stopping is almost certain. Think of Wegovy as a tool that makes healthy eating dramatically easier — you still need to choose the right foods.
For a structured eating plan, see our semaglutide diet plan for South Africa and foods to avoid on semaglutide.
Exercise is non-negotiable on Wegovy — not primarily for calorie burning, but to preserve muscle mass. Rapid weight loss without resistance training means you lose muscle alongside fat, which tanks your metabolism and leaves you weaker.
The landmark STEP clinical trial programme (involving over 15,000 participants) showed consistent results for Wegovy:
In practical terms for South Africans: If you weigh 100kg, expect to lose 12-15kg over 12-18 months on Wegovy with proper diet and exercise. Most of the weight loss occurs in the first 6-9 months, then plateaus. Weight loss is faster in people without type 2 diabetes and in those who combine Wegovy with a structured eating plan.
| Timeframe | Expected progress |
|---|---|
| Month 1-2 | 1-3% body weight loss. Appetite starting to decrease. Dose escalation phase |
| Month 3-4 | 4-7% body weight loss. Noticeable changes in clothing fit. Energy improving |
| Month 5-8 | 8-12% body weight loss. Significant visible changes. Blood markers improving |
| Month 9-12 | 12-15% body weight loss. Approaching maximum effect. Blood pressure, cholesterol, and blood sugar substantially improved |
| Month 12+ | Plateau phase. Weight stabilises. Focus shifts to maintenance and preventing regain |
For a more detailed month-by-month breakdown, see our semaglutide weight loss timeline.
This is the critical question most patients do not ask until it is too late. The STEP 4 trial data is clear: stopping semaglutide leads to significant weight regain.
This does not mean Wegovy is pointless — it means you should plan for the long term. Options include:
Read our full article: Weight regain after stopping semaglutide.
Menopausal women face unique challenges with semaglutide — from bone density concerns to HRT interactions. Wegovy can be effective but requires careful monitoring. Read our dedicated guide: Ozempic and menopause in South Africa.
Polycystic ovary syndrome drives insulin resistance and weight gain. Semaglutide can help with both, and may improve fertility in some cases. See: Ozempic for PCOS in South Africa.
If you have type 2 diabetes, your doctor may prefer Ozempic (specifically approved for diabetes) or may use Wegovy if weight management is the primary goal. Blood sugar monitoring is essential. Read: Ozempic and diabetes in South Africa.
Muscle preservation becomes critical. Higher protein intake and mandatory resistance training are essential for older adults on semaglutide. See: Weight loss after 50 in South Africa.
Yes, Wegovy has been registered by SAHPRA. However, availability has been inconsistent due to global supply constraints from Novo Nordisk. Many pharmacies experience stock shortages. Check Dis-Chem, Clicks, or independent pharmacies, and ask your doctor about Ozempic as an alternative when Wegovy is unavailable.
Approximately R4,500 to R6,500 per month, depending on the dose tier. The maintenance dose (2.4mg) is at the higher end. Most medical aids do not cover Wegovy for weight loss, though some premium plans may provide partial cover with a specialist motivation letter.
Any registered South African doctor (GP or specialist) can prescribe Wegovy. However, a motivation letter from an endocrinologist or bariatric physician carries more weight with medical aid schemes if you are seeking cover. GPs are more likely to prescribe Ozempic off-label than Wegovy due to familiarity.
There is no fixed duration. Clinical data shows that stopping semaglutide leads to weight regain in the majority of patients. Many doctors now recommend long-term or indefinite use, similar to blood pressure or cholesterol medication. Discuss a personalised plan with your prescribing doctor.
Yes. Because both contain semaglutide, switching is straightforward. Your doctor will match the dose as closely as possible. The most common switch is from Ozempic 1mg to Wegovy 1.7mg or 2.4mg when a higher dose is needed for weight loss. No washout period is required.
Semaglutide has been studied for up to 2 years in the STEP trials with a favourable safety profile. The SELECT cardiovascular outcomes trial (2023) showed semaglutide reduced the risk of major cardiovascular events by 20% in overweight adults. Long-term data beyond 5 years is still limited, as with any relatively new medication class. Regular medical check-ups are recommended while on treatment.
Wegovy contains semaglutide (a GLP-1 agonist). Mounjaro contains tirzepatide (a dual GIP/GLP-1 agonist) which targets two hormonal pathways instead of one. Clinical trials suggest Mounjaro may produce greater weight loss (up to 22% body weight) but it is newer and availability in South Africa is still building. See our Mounjaro guide and medication comparison for full details.
Compare all GLP-1 medications available in South Africa, including costs, efficacy, and availability.
Compare Weight Loss MedicationsDisclaimer: This article is for informational purposes only and does not constitute medical advice. Weight loss medications carry risks and should only be used under medical supervision. Consult your doctor or endocrinologist before starting, stopping, or changing any medication. Prices are approximate and may vary by pharmacy and location.